In a bid to bolster its immuno-oncology portfolio, Janssen Biotech has agreed to partner with Fate Therapeutics to develop induced pluripotent stem cell (iPSC)-derived product candidates for up to four tumour-associated antigen targets. The deal, which is worth up to US$4.6 B, combines Fate’s iPSC product platform with Janssen’s scientific and commercialisation expertise to develop off-the-shelf immunotherapies that overcome numerous limitations associated with the production of cell therapies using patient-sourced cells.